Novocure Ltd. (NVCR)

45.11
0.14 0.31
NASDAQ
Prev Close 44.97
Open 45.09
Day Low/High 44.26 / 45.69
52 Wk Low/High 19.55 / 54.11
Volume 252.88K
Exchange NASDAQ
Shares Outstanding 95.64B
Market Cap 4.13B
Div & Yield N.A. (N.A)

Latest News

Novocure To Report First Quarter 2019 Financial Results

Novocure To Report First Quarter 2019 Financial Results

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.

Novocure Initiates Phase 3 Pivotal Trial In Recurrent Ovarian Cancer

Novocure Initiates Phase 3 Pivotal Trial In Recurrent Ovarian Cancer

Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Novocure Announces 48 Presentations And A Symposium Session On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2019

Novocure Announces 48 Presentations And A Symposium Session On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2019

Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2019, March 29 through April 3, in Atlanta.

Novocure's Chief Science Officer Retires After 17 Years Of Service

Novocure's Chief Science Officer Retires After 17 Years Of Service

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research and Development, effective May 1, 2019.

Novocure To Participate In Oppenheimer's 29th Annual Healthcare Conference

Novocure To Participate In Oppenheimer's 29th Annual Healthcare Conference

Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure's Chief Financial Officer, will participate in Oppenheimer's 29 th Annual Healthcare Conference on March 20, 2019, in New York City.

Novocure Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Company Update

Novocure Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2018, highlighting continued revenue growth, anticipated clinical and regulatory milestones and a strong cash position.

Novocure Announces Fourth Quarter And Full Year 2018 Operating Statistics, Preliminary Net Revenues And Provides Company Update

Novocure Announces Fourth Quarter And Full Year 2018 Operating Statistics, Preliminary Net Revenues And Provides Company Update

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2018.

Novocure To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Novocure To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) will participate in the 37 th Annual J.P.

Novocure And The AACR Announce Four Inaugural Research Grants To Promote And Support Innovative Research On Tumor Treating Fields

Novocure And The AACR Announce Four Inaugural Research Grants To Promote And Support Innovative Research On Tumor Treating Fields

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants.

Sub-Group Analysis Of Novocure's EF-14 Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Published In Journal Of Neuro-Oncology Demonstrating More Time On Optune® Predicted Increased Survival

Sub-Group Analysis Of Novocure's EF-14 Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Published In Journal Of Neuro-Oncology Demonstrating More Time On Optune® Predicted Increased Survival

Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology.

Novocure And Zai Lab Awarded Deal Of The Year At 5th Annual BioCentury China Healthcare Summit In Shanghai, China

Novocure And Zai Lab Awarded Deal Of The Year At 5th Annual BioCentury China Healthcare Summit In Shanghai, China

Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5 th annual BioCentury China Healthcare Summit in Shanghai, China.

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces More Than 70 Presentations On Tumor Treating Fields At 23rd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations, will be featured at the 23rd Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov.

Novocure And Zai Lab To Host Investor Event

Novocure And Zai Lab To Host Investor Event

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov.

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure Reports Third Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2018.

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Lululemon Athletica, Starbucks, Snap: 'Mad Money' Lightning Round

Jim Cramer weighs in on Lululemon Athletica, Ollie's Bargain Outlet, Burlington Stores, Snap, Blackstone Group, NovoCure, Starbucks, Weight Watchers and more.

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure Founder Professor Yoram Palti And Director Louis J. Lavigne, Jr. Retire From Board Of Directors

Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J.

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Higher Delivered Dose Of Tumor Treating Fields To Tumor Bed Associated With Improved Overall Survival In Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today results from a post-hoc analysis of Novocure's EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) that demonstrated that a higher dose of Tumor Treating Fields delivered to the tumor bed was...

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Pancreatology Publishes Results Of The PANOVA Phase 2 Pilot Trial In Advanced Pancreatic Cancer Suggesting Improved Survival Of Patients Treated With Tumor Treating Fields

Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial have been published in Pancreatology .

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure Announces That The Medicare DME MACs Have Accepted The Local Coverage Determination Reconsideration Request For Optune®

Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma...

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure Announces 55 Presentations At European Association Of Neuro-Oncology Meeting 2018

Novocure (NASDAQ: NVCR) announced today 55 presentations on Tumor Treating Fields at the European Association of Neuro-Oncology (EANO) Meeting 2018, Oct.

Novocure To Report Third Quarter 2018 Financial Results

Novocure To Report Third Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Novocure (NASDAQ: NVCR) announced today that results from its STELLAR phase 2 registration trial in mesothelioma will be highlighted in an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the...

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure (NASDAQ:NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement...

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Novocure (NASDAQ: NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care...

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic...

Novocure To Present At Two Upcoming Investor Conferences

Novocure To Present At Two Upcoming Investor Conferences

Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences.

Novocure Announces Addition To Its Board Of Directors

Novocure Announces Addition To Its Board Of Directors

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure's board in July 2018.

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology.

TheStreet Quant Rating: D (Sell)